VisionWave Holdings, Inc.
VWAVWDrugs in Pipeline
9
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Ad26.ZEBOV
Ebola Virus Disease
Intravitreous injection of ranibizumab
High Risk Proliferative Diabetic Retinopathy
rebamipide 2% ophthalmic suspension
Keratoconjunctivitis Sicca
IVMED-80
Keratoconus
ACU-4429
Dry Age-related Macular Degeneration
SHJ002
Corneal Erosion
Emixustat
Stargardt Disease
AdvVEGF-D
Refractory Angina Pectoris
BHVI1 eye drops
Myopia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ad26.ZEBOV | Phase 3 | Ebola Virus Disease | - | - |
Intravitreous injection of ranibizumab | Phase 3 | High Risk Proliferative Diabetic Retinopathy | - | - |
rebamipide 2% ophthalmic suspension | Phase 3 | Keratoconjunctivitis Sicca | - | - |
IVMED-80 | Phase 2 | Keratoconus | - | - |
ACU-4429 | Phase 2 | Dry Age-related Macular Degeneration | - | - |
SHJ002 | Phase 2 | Corneal Erosion | - | - |
Emixustat | Phase 2 | Stargardt Disease | - | - |
AdvVEGF-D | Phase 2 | Refractory Angina Pectoris | - | - |
BHVI1 eye drops | Phase 2 | Myopia | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in VisionWave Holdings, Inc.'s drug pipeline?→
CatalystAlert tracks 9 drug candidates in VisionWave Holdings, Inc.'s (VWAVW) pipeline across Phase 3, Phase 2. Its lead program is Ad26.ZEBOV (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is VisionWave Holdings, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for VisionWave Holdings, Inc. (VWAVW) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track VWAVW biotech catalysts?→
Add VWAVW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow VisionWave Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.